For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - For dose escalation monotherapy: CLL, HL, NHL, MM - For dose expansion monotherapy: CLL, HL, NHL - For dose escalation and dose expansion in combination with BMS-936558: HL and DLBCL - Progressed, or been intolerant to, at least one standard treatment regimen - Not eligible for or declined transplantation or any standard therapy known to be life prolonging or life saving - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - At least 1 lesion with measurable disease at baseline - Availability of an existing tumor biopsy sample (or consent to allow pre-treatment tumor biopsy if sample not available) Exclusion Criteria: - Known or suspected central nervous system (CNS) metastases or with the CNS as the only site of active disease (controlled CNS metastases are allowed) - Autoimmune disease - Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent - Uncontrolled or significant cardiovascular disease Other protocol defined inclusion/exclusion criteria could apply